Condition Directory

Breast Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 15, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7089

Shown on this page

Current sort

How Breast Cancer studies are organized in the registry

Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.

Terms that often appear in related listings

triple-negative HER2-positive hormone receptor-positive metastatic breast cancer

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 877–888 of 7,089 matching trials for Breast Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions: Educational Video and QPL List, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Transcutaneous vagus nerve and acupuncture point stimulation; Device
Lead sponsor: The Healing Consciousness Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Meadowbrook, Pennsylvania

Conditions: Breast Cancer, Quality of Life, Breast Cancer, Metastatic, Breast Cancer, Metastatic Breast Cancer, Leptomeningeal Metastasis of Breast Cancer, Brain Metastases From Breast Cancer
Interventions: Health-Related Quality of Life (QOL) questionnaires, Medical Chart Review; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions: Aromatase Inhibitors, Bupropion, GnRH agonist; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: Tamoxifen, Anastrozole, Degarelix, Abemaciclib; Drug
Lead sponsor: Jose Pablo Leone; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Boston, Massachusetts + 6 more

Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 207
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more

Conditions: Breast Cancer, HER2-positive
Interventions: Zanidatamab, Letrozole, Tamoxifen; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer
Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Liver Cancer, Head and Neck Cancer, Melanoma
Interventions: Hello for Cancer game, Table Topics game; Behavioral · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: HER2-negative Breast Cancer Patients With Brain Metastases
Interventions: Utidelone, Utidelone in combination with capecitabine; Drug
Lead sponsor: Biostar Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 9 more

Conditions: Breast Cancer
Interventions: GDC-0587, Giredestrant, Omeprazole; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Grand Rapids, Michigan • San Antonio, Texas

About this Breast Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Breast Cancer clinical trials

How Breast Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors

Quality of Life for Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

ETHAN - ET for Male BC

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

About this Breast Cancer clinical trials directory page